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INTRODUCTION
Patients who relapse after high-dose therapy and autolo-
gous stem cell transplantation (SCT) have limited treatment
options. A second autologous transplantation may be pallia-
tive for a minority of patients but is unlikely to be curative.
Some patients may be cured with allogeneic SCT, but at the
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ABSTRACT
Allogeneic donor leukocytes can be used after nonmyeloablative conditioning to exploit their graft-versus-tumor
(GVT) activity in the setting of reduced conditioning-regimen toxicity. This approach may be particularly useful for
patients who relapse after autologous stem cell transplantation (SCT). However, GVT activity, toxicity, and ability
to establish mixed chimerism may differ in patients who were heavily pretreated prior to SCT compared with
patients treated earlier in the course of their disease. We have performed a series of studies of nonmyeloablative
allogeneic transplantation and present data on the subset of 14 patients treated for relapse after autologous SCT: 4
patients received no conditioning and unstimulated donor leukocyte infusions (DLI), 10 patients received condi-
tioning with fludarabine and cyclophosphamide followed by unstimulated or granulocyte-colony–stimulating factor
(G-CSF)-stimulated allogeneic peripheral blood stem cells (PBSCs), 4 patients received no graft-versus-host disease
(GVHD) prophylaxis, and 10 patients received cyclosporine GVHD prophylaxis. All but 1 patient had sustained
donor chimerism at least 30 days after allogeneic cell therapy (ACT), and 8 patients had more than 80% donor
chimerism after ACT. Acute GVHD developed in 11 patients (grade III-IV, n = 6). Aplasia was more frequent in the
patients receiving unstimulated PBSCs, despite the development of mixed chimerism. There were 6 complete
responses and 4 partial responses; response was independent of conditioning and growth-factor stimulation of the
donor graft. Five patients died of treatment-related causes and 4 patients died from progressive disease. Four
patients remained alive 27 to 194 weeks (median, 66 weeks) after ACT. Prior autologous SCT may define a subset
of patients at particularly high risk for GVHD and other toxicity after ACT. However, these data show that ACT
with either DLI or G-CSF–stimulated blood cells results in direct GVT activity in some patients with Hodgkin’s
disease, myeloma, and non-Hodgkin’s lymphoma, even after relapse from autologous SCT. Most patients developed
donor chimerism with minimal conditioning. Alternative prophylactic regimens that control GVHD while maintain-
ing GVT are needed to improve outcomes in these heavily pretreated patients.
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expense of extensive morbidity and mortality. Regimen-
related toxicity and graft-versus-host disease (GVHD) result
in nonrelapse mortality rates ranging from 25% to greater
than 50%, and less than 25% to 35% of patients experience
prolonged disease-free survival [1-3]. Safer, more effective
therapies for these patients are clearly needed.
A major advantage of allogeneic cell therapy (ACT) for
these patients is the potential to generate a graft-versus-tumor
(GVT) reaction. A potent GVT effect has been demonstrated
after allogeneic bone marrow transplantation (BMT) [4] and
with the use of donor leukocyte infusions (DLI) to treat relapse
after allogeneic BMT [5-9]. The GVT effect is mediated, at
least in part, by donor T cells and may partially account for the
lower relapse rates seen after allogeneic SCT for Hodgkin’s
disease, non-Hodgkin’s lymphoma (NHL), and other diseases
compared with relapse rates associated with autologous
hematopoietic stem cell transplantation (HSCT).
For some diseases susceptible to immunologic control,
generation of a GVT effect may be possible without the need
for intensive myeloablation. The goal of ACT is to generate
long-term engraftment of allogeneic donor lymphocytes
capable of mediating an antitumor reaction with minimal-
intensity conditioning therapy. We have shown that in heavily
pretreated patients unstimulated DLI can generate long-term
mixed chimerism without the need for any conditioning ther-
apy and that donor lymphocytes in these patients can induce a
direct GVT reaction [10]. However, the use of a nonmye-
loablative immunosuppressive conditioning therapy before
ACT may further enhance donor-cell engraftment and,
hence, generation of GVT activity, and this treatment option
has been applied to patients with a variety of malignancies
[11-14]. It is hoped that this approach will minimize condi-
tioning-regimen toxicity and exploit the GVT potential of
allogeneic donor cells. This strategy is especially attractive for
heavily pretreated patients who have received prior high-dose
chemotherapy when regimen-related toxicity from second
SCT is anticipated to be prohibitive.
Although the use of nonmyeloablative conditioning and
ACT treatment is increasing, many issues remain unre-
solved. The intensity of the conditioning regimen required
to permit sustained engraftment is not deﬁned. Because the
effectiveness of ACT depends largely on immunologic
mechanisms, it is preferable to use the least intensive condi-
tioning regimen that allows sufﬁcient chimerism to provide a
GVT response. Various reports show that donor hemato-
poietic chimerism can occur in some patients without any
conditioning therapy [10] and with variably intense condi-
tioning regimens including low-dose fludarabine and
cyclophosphamide [12], low-dose total body irradiation [15],
and nonablative but intensive doses of more traditional
chemotherapeutic agents [11,13]. Patients who have received
prior high-dose therapy and autologous HSCT are often
immunocompromised. Thus, when ACT is used to treat
patients who have already undergone autologous HSCT, the
use of minimal conditioning may be possible. Another unre-
solved issue is the appropriate graft composition. Because a
GVT reaction rather than hematopoietic engraftment is the
endpoint, and unstimulated DLI may be insufficient to
generate a GVT effect, we have used both unstimulated
donor leukocytes and granulocyte-colony–stimulating fac-
tor (G-CSF)-stimulated peripheral blood mononuclear cell
grafts. Additional factors that are not well delineated are the
risk of GVHD and the appropriate immunosuppressive pro-
phylaxis. Prophylaxis use has varied from no prophylaxis in
some cases [10,12] to the use of cyclosporine (CSA) alone
[13,14,16,17] and the use of CSA or FK506 with methotrex-
ate, steroids, or mycophenolate moeftil [11,15,18]. It is very
likely that conditioning-regimen requirements, GVHD pro-
phylaxis, toxicity, and responses may vary according to dis-
ease status and extent of prior therapy.
In order to address nonmyeloablative conditioning and
ACT treatment issues, we performed sequential trials of
nonmyeloablative allogeneic transplantation. These trials
included 14 patients with relapse after autologous SCT for
treatment of Hodgkin’s disease, NHL, or myeloma. These
14 patients represented a subset of all patients treated in
these sequential trials. Our goal was to determine the mini-
mum therapy needed to establish mixed chimerism, avoid
marrow aplasia, and prevent GVHD. We also wanted to
evaluate factors associated with toxicity and GVT induction
in this high-risk group of patients.
PATIENTS AND METHODS
Eligibility Criteria
Patients aged 18 to 72 years were eligible for 2 sequential
trials of ACT if they had a relapsed hematologic malignancy
that was incurable with standard therapy. Eligible patients
were unsuitable candidates for traditional allogeneic SCT
because of extensive pretreatment with high-dose therapy and
autologous transplantation, age, or comorbid disease. All but
1 patient had an HLA-identical sibling donor. Class I antigens
were deﬁned by serologic methods, and class II alleles were
defined by high-resolution DNA typing. Other eligibility
requirements included the presence of measurable disease, no
prior antitumor therapy within 4 weeks of study entry, an
Eastern Cooperative Oncology Group performance status of
0 to 2, adequate kidney and liver function, and a life expectancy
greater than 3 months. Donors were eligible if they were aged
16 to 72 years with no contraindication for leukapheresis.
Written informed consent was obtained from all patients and
donors under the guidelines of the institutional review boards
at the centers providing treatment. Patients were treated at the
University of Pennsylvania (n = 10), Brigham and Women’s
Hospital (n = 2), or Fairfax-Inova Hospital (n = 1).
Allogeneic Cell Therapy
ACT was administered on 14 occasions to 13 different
patients; this number represents a subset of patients treated
during 2 sequential trials of ACT. From April 1995 to Janu-
ary 1997, 4 patients were treated with interferon-α followed
by unstimulated DLI (Trial 1). Data regarding Trial 1 has
been reported previously [10]. Subsequently, 11 patients
were treated with nonmyeloablative chemotherapy followed
by unstimulated DLI (n = 4) or G-CSF–mobilized peripheral
blood stem cell (PBSC) infusions (n = 7) (Trial 2). These
patients were pretreated with ﬂudarabine (30 mg/m2 per day
for 3 days) and cyclophosphamide (300 mg/m2 per day for
3 days) because of the anticipated immunosuppressive effects
of this regimen and the favorable toxicity proﬁle. ACT was
administered 7 to 10 days after the start of chemotherapy.
Cells for unstimulated DLI were collected from the donor
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by leukapheresis on 1 to 4 occasions to provide recipients
with a minimum cell dose of 2 × 108 mononuclear cells/kg.
Dosage determination was based on prior trials of DLI as a
treatment for relapse after allogeneic BMT [7]. To obtain
cells for stimulated PBSC infusions, donors were treated
with subcutaneously injected G-CSF at 10 µg/kg per day.
Leukapheresis was performed on day 5; G-CSF continued
until stem cell collections were completed. Leukapheresis
was carried out on 1 to 3 sequential days to collect 2 × 108
mononuclear cells/kg or a minimum of 2 × 106 CD34+
cells/kg. All donor products were collected through periph-
eral intravenous access. All but 1 product was freshly infused
on the day of collection; 1 donor underwent leukapheresis
and cells were stored frozen until the time of infusion. The
total cumulative dose of cells infused is shown in Table 2.
One patient is included twice in the study, as patient 4
and patient 14. This patient achieved a complete response
(CR) on Trial 1 and relapsed 33 months later with no evi-
dence of mixed chimerism; 38 months after Trial 1 he
entered Trial 2 and was treated with nonmyeloablative con-
ditioning and G-CSF–stimulated PBSC infusions. Given
the differences in the trials, the lack of mixed chimerism,
and the time between enrollments, each course of ACT for
this patient is reported separately.
GVHD Prophylaxis
No GVHD prophylaxis was administered to the first
4 recipients of primary DLI (Trial 1). The 10 recipients of non-
myeloablative chemotherapy (Trial 2) began receiving CSA on
day –1 of transplantation. CSA was titrated to maintain thera-
peutic levels of 200 to 300 ng/mL, assayed in most cases by
high-performance liquid chromatography. If patients had no
evidence of acute GVHD, CSA was tapered by approximately
10% to 20% per week beginning day 30 after transplantation.
Chimerism Analysis
Polymerase chain reaction (PCR) using primers speciﬁc
for several heterogeneous short tandem-repeat loci was used
prior to DLI to identify 1 locus with patient- and donor-
speciﬁc alleles. Subsequently, primers for the distinguishing
loci were used to determine the presence of donor cells in
recipient whole blood or bone marrow at different time
points after ACT. DNA was extracted from white blood
cells using QIAamp DNA Blood Minikit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions, except
that a 100-µL elution volume was used. DNA (10 ng) was
used for PCR ampliﬁcation with ﬂuorescent-labeled primers
using the GenePrint system (Promega Corp, Madison, WI).
PCR products were analyzed by capillary electrophoresis
using an ABI PRISM 310 Genetic Analyzer (Perkin-Elmer
Biosystems, Foster City, CA) followed by analysis with
GENESCAN and Genotyper software for peak identiﬁca-
tion and peak area determination (Perkin-Elmer Biosystems).
Allele repeat numbers were determined by comparison with
an allelic ladder of known repeat sizes. Each assay included
pre-ACT recipient and donor DNA and a no-DNA control.
The percentage of donor cells present in the postinfusion
specimen was calculated as the ratio of the peak area of
donor-specific alleles to the peak area of recipient-specific
alleles. These methods provide semiquantitative data and
reliably detect 0.5% to 1% of donor DNA.
Samples were assayed for detectable donor DNA prior
to and within 30 to 60 minutes after donor cell infusions.
Samples assayed immediately after donor cell infusion were
scored as negative or positive for detectable donor cells
(early chimerism). Sustained chimerism was defined as
detectable donor DNA from peripheral blood samples more
than 4 weeks after the ﬁnal infusion.
Evaluation of Patient Response
Patients were evaluated every 1 to 2 weeks after the ﬁnal
donor mononuclear cell infusion for evidence of response and
GVHD. Acute GVHD was graded according to criteria out-
lined in the consensus conference of GVHD grading [19].
Evaluations of patients who died within 4 weeks of ACT were
not included in response or GVHD assessment data. Biopsies
of affected organs were performed when indicated to conﬁrm
acute GVHD. Blood for chimerism analysis was collected
weekly for 4 weeks and then at least monthly after ACT.
Clinical response was determined 4 weeks after ACT and
then every 2 to 3 months after ACT. Responses were catego-
rized as complete response (CR) (disappearance of all measur-
able disease), partial response (PR) (at least 50% reduction in
measurable tumor), no change (less than 50% decrease or less
than 25% increase over original measurements), or progres-
sion (increase greater than or equal to 25% over original
measurements or occurrence of new lesions). Minor response
was deﬁned as a 20% to 50% decrease in measurable disease
or index lesion that did not meet the above criteria.
Data Analysis
Data were analyzed at the University of Pennsylvania
with the aid of the Statview statistical software package
(Abacus Concepts, Berkeley, CA).
RESULTS
Patient Characteristics
The characteristics of the 14 patients studied are shown
in Table 1. Nine male and 5 female patients with a median
Table 1. Patient Characteristics*
Age, median (range), y 36 (12-63)
No. of men 9
No. of women 5
Donor age, median (range), y 30 (16-51)
No. of sex-mismatched donors 5
Diagnosis
No. with Hodgkin’s disease 11
No. with myeloma 2
No. with NHL 1
No. of prior chemotherapy regimens† 
No. of patients receiving 2 6
No. of patients receiving 3 5
No. of patients receiving 4 2
No. of patients receiving 5 1
No. of weeks from autologous SCT 45 (24-202)
to ACT, median (range)
*NHL indicates non-Hodgkin’s lymphoma; SCT, stem cell trans-
plantation; ACT, allogeneic cell therapy. 
†Prior regimens occurred before ACT, excluding autologous SCT
conditioning therapy.
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age of 37 years (range, 12-63 years) received ACT for
relapsed Hodgkin’s disease (n = 11), relapsed myeloma
(n = 2), or relapsed NHL (n = 1). Donors were completely
HLA-matched siblings in 13 cases; 1 patient was treated
with donor cells from a 4-of-6 HLA-matched cousin. The
donor and recipient were of opposite sex in 5 cases.
Prior to ACT and excluding high-dose therapy and
autologous HSCT, all patients received 2 or more different
conventional chemotherapy regimens as shown in Table 1.
All patients received high-dose therapy and autologous
HSCT for relapsed or refractory disease. The median time
from HSCT to relapse was 19 weeks (range, 10-35 weeks).
After relapse from HSCT, 5 patients had received ACT as
the next treatment, and 9 patients had received 1 (n = 6), 2 (n
= 2), or 3 (n = 1) different regimens as salvage therapy prior
to ACT. No patient had received prior therapy within
4 weeks of conditioning prior to ACT. At the time of ACT,
5 patients had an untreated relapse, 6 had refractory disease,
2 had relapsed after response to salvage therapy, and
1 patient had a PR to salvage therapy. The median time from
autologous SCT to ACT was 48 weeks (range 19-232 weeks).
Allogeneic Cell Therapy
Patients 1 to 4 received no conditioning therapy, and
their data have been described previously [10]. Subsequent
patients received nonmyeloablative conditioning therapy, a
strategy based on our experience and emerging data [11,12].
Fludarabine and cyclophosphamide were administered in
the outpatient clinic in 8 cases and in an inpatient setting in
2 cases, without any signiﬁcant complications. All patients
either received ACT as outpatients or were discharged from
the hospital immediately after allogeneic cell infusion. No
patient required admission for neutropenic fevers and no
major complications were associated with the conditioning
therapy or allogeneic cell infusion.
The graft characteristics are shown in Table 2. In 7 cases
in which unstimulated donor leukocyte products were given,
the donor product contained a median of 2.2 × 108 mononu-
clear cells/kg (range, 0.9-6.21 × 108 cells/kg), and 0.7 × 108
CD3+ cells/kg (range, 0.48-2.7 × 108 cells/kg). In 7 cases in
which G-CSF–mobilized donor cells were used for ACT,
the products contained a median of 5.5 × 108 mononuclear
cells/kg (range, 2.4-8.7 × 108 cells/kg) and 3.6 × 106 CD34+
cells/kg (range, 0.9-6.1 × 106 cells/kg); these patients
received a median of 1.85 × 108 CD3+ cells/kg (range, 1.1-
4.1 × 108 cells/kg).
Response to ACT
Of the 14 patients, 10 (71%) responded to ACT (Table 3).
Of the 10 responding patients, 6 had a complete remission,
including 4 patients treated for Hodgkin’s disease, 1 patient
treated for NHL, and 1 patient treated for myeloma. Four
patients had PRs (Hodgkin’s disease, n = 3; myeloma, n = 1).
One patient with Hodgkin’s disease had initial regression of
disease not meeting criteria for PR (minor response) but
died of progressive infection 5 weeks after ACT (the details
of this patient’s course were previously described [10]. Two
patients with Hodgkin’s disease had no response or progres-
sive disease and 2 additional patients with Hodgkin’s disease
were not evaluable because of early death.
Response to ACT was not dependent on the graft
source (DLI versus PBSCs). Four of 7 recipients of DLI
responded (3 CR, 1 PR), and 5 of 7 recipients of PBSCs
responded (3 CR, 2 PR).
Donor Chimerism
All but 1 patient had detectable donor cells in the
peripheral blood by day 30 after ACT. At approximately
30 days after ACT, donor chimerism in all patients was 0%
to 99% (median, 8.5%). Eight patients had greater than
80% donor chimerism at some time after ACT.
Of the 7 patients who received DLI as ACT, 5 had 1%
to 5% donor chimerism at least 30 days after ACT. Mixed
chimerism of 1% to 5% was sustained throughout follow-up
in 5 patients. One patient was not evaluable for donor
chimerism because of early death, and only 1 recipient of
DLI did not have detectable donor cells after initial ACT
administered without nonmyeloablative therapy. This
patient did experience transient donor chimerism after a
second course of DLI conditioned with low-dose cyclophos-
phamide as previously described [10]. Two recipients of
unmobilized DLI required additional donor bone marrow
to reverse marrow aplasia and had 99% to 100% donor
chimerism after marrow infusion.
Of the 7 recipients of G-CSF–mobilized PBSCs, 6 had
evidence of donor chimerism (2% to 99%) approximately
30 days after ACT. Patient 2 had 11% donor chimerism on day
11 but subsequent testing showed only autologous recovery.
Interestingly, this patient went on to achieve CR with resolu-
tion of all evidence of disease except for persistent osteolytic
abnormalities seen on plain x-rays. All other patients had sus-
tained donor chimerism. The 7 recipients of PBSC grafts had a
median of 99% donor chimerism (range, 11%-100%). The
kinetics of engraftment and maximum donor chimerism for
this group of patients are illustrated (Figure). Engraftment
rates were variable; some patients achieved their maximum
donor chimerism rapidly whereas a gradual increase in donor
chimerism was noted in others, as illustrated. As can be seen,
these 7 patients achieved their maximum donor chimerism a
median of 43 days after ACT (range, 16-187 days).
Graft-Versus-Host Disease
Acute GVHD occurred in 11 patients, including
6 patients (42%) with grade III-IV GVHD as shown in
Table 2. Graft Characteristics*
Total NucleatedCells/kg,
Graft Source Median (Range), × 108 CD3+ Cells/kg, Median (Range), × 108 CD34+ Cells/kg, Median (Range), × 108
Unstimulated DLI 2.2 (0.9-9.8) 0.48 (0.5-2.7) ND
G-CSF mobilized PBSCs 5.5 (2.4-8.7) 1.9 (1.1-4.1) 3.6 (0.9-6.1)
*DLI indicates donor leukocyte infusions; ND, not done; G-CSF, granulocyte colony-stimulating factor; PBSC, peripheral blood stem cell.
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Table 4. GVHD contributed to death in 3 patients. All
4 patients treated with DLI without nonmyeloablative
chemotherapy received no GVHD prophylaxis and devel-
oped grade I (n = 1), grade II (n = 2), or grade IV (n = 1)
acute GVHD. Ten patients received CSA as GVHD prophy-
laxis and 7 developed acute GVHD. Of these 10 patients, 3
received DLI as the graft source and 2 developed grade III
GVHD. All 7 recipients of allogeneic PBSCs received
GVHD prophylaxis with CSA and 5 (71%) experienced
acute GVHD; these included 2 patients with grade I and
3 patients with grade III acute GVHD. The 1 recipient of mis-
matched donor stem cells developed grade III acute GVHD.
Marrow Aplasia
Of the 7 recipients of unstimulated donor leukocytes, 3
developed severe pancytopenia and marrow aplasia. One
patient previously described was treated with DLI without
nonmyeloablative chemotherapy and developed pancytope-
nia and marrow aplasia associated with severe acute
GVHD. This patient died 5 weeks after ACT from compli-
cations of GVHD and infection. Two patients treated with
ﬂudarabine and cyclophosphamide prior to ACT developed
aplasia. In 1 of these patients, marrow aplasia was associated
with severe acute GVHD, and the other patient had no
signs of acute GVHD. Both patients received an infusion of
donor bone marrow for persistent pancytopenia and both
patients experienced full donor hematopoietic recovery.
One patient with myeloma was in complete remission prior
to and after the bone marrow infusion and 1 patient with
Hodgkin’s disease had no response after either DLI or bone
marrow rescue. Given the incidence of marrow aplasia, the
subsequent 7 patients received G-CSF–mobilized periph-
eral blood products as ACT, and none of these patients
developed marrow aplasia.
Other Toxicity After ACT
In addition to the anticipated toxicity of GVHD and
marrow aplasia, several unanticipated severe complications
occurred in this cohort of patients. Cytomegalovirus disease
was diagnosed in 2 patients, requiring hospitalization and
antiviral therapy. One patient died of pneumonia and unex-
plained neurologic toxicity that may have been related to
CSA. At autopsy, mucomycosis was identiﬁed as the cause
of pulmonary inﬁltrates. Patient 8, treated with ﬂudarabine
and cyclophosphamide, had progressive neurotoxicity con-
sistent with possible progressive multifocal leukoen-
cephalopathy (PML). This patient had relapsed Hodgkin’s
disease 4 months after autologous HSCT. She received
ACT 2 months later and had >99% donor chimerism
within 30 days without evidence of GVHD. Five weeks
after treatment, she developed progressive and debilitating
ataxia, slurred speech, and visual changes. A magnetic reso-
nance imaging scan was suggestive of PML, and CD4
counts were low at 77/µL. Given her progressive deterioration
Table 3. Outcome After Allogeneic Cell Therapy (ACT)*
Acute Weeks 
Allogeneic Maximum GVHD Outcome, From ACT 
Patient Preinfusion Cell MNC, CD34, Donor Grade Disease to Last
No. Diagnosis Treatment Source ×108/kg ×106/kg Chimerism†(Maximum) Response Status Follow-Up
1 Myeloma Interferon DLI 6.21 NE 5% II PR Died, PD 16
2 Hodgkin’s disease Interferon DLI 4.15 NE NE IV Minor‡ Died, GVHD 5
and infection
3 Hodgkin’s disease Interferon DLI 2.55 NE 5% II NE§ Died, PD 5
4 Hodgkin’s disease Interferon DLI 2.2 NE ND I CR Alive, active disease. 194 
Underwent second 
ACT
5 Myeloma Flu/Cy DLI 1.34 NE 99% III CR Died in CR, GVHD 25 
and infection
6 Hodgkin’s disease Flu/Cy DLI 1.2 NE 100% 0 NR Alive, active disease 79
7 Non-Hodgkin’s Flu/Cy DLI 0.9 NE 8% III CR Died in CR, neurologic 8
lymphoma toxicity and infection
8 Hodgkin’s disease Flu/Cy PBSC 4.7 ND 100% 0 PR Alive, active disease 53
9 Hodgkin’s disease Flu/Cy PBSC 2.7 0.9 99% III CR Died PD, relapsed 36
after CR
10 Hodgkin’s disease Flu/Cy PBSC 8.7 ND 99% III CR Died in CR, GVHD and 14
infection
11 Hodgkin’s disease Flu/Cy PBSC 5.5 6.1 88% I NE Died, PD 4
12 Hodgkin’s disease Flu/Cy PBSC 3.3 2.1 96% I PR Died, GVHD and 19 
infection
13 Hodgkin’s disease Flu/Cy PBSC 8.5 3.6 98% III PR Alive, active disease 27
14 Hodgkin’s disease Flu/Cy PBSC 5.5 4.5 0% 0 CR Alive in CR 33
*MNC indicates mononuclear cells; GVHD, graft-versus-host disease; DLI, donor leukocyte infusions; NE, not evaluable; PR, partial response; PD,
progressive disease; ND, not done; CR, complete response; Flu/Cy, ﬂudarabine/cyclophosphamide; NR, no response; PBSC, peripheral blood stem cell.
†Chimerism studies are reported for peripheral blood samples. 
‡This patient had a minor response but did not ﬁt criteria for a PR.
§This patient survived longer than 4 weeks (5 weeks) after ACT but did not have repeat staging studies done due to medical complications and
therefore was NE for response.
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and the high suspicion for PML, infusional interleukin-2
was started. The patient experienced marked improvement
in her neurologic symptoms concurrent with a rise in the
CD4 count to greater than 800/µL. Interleukin-2 did not
induce GVHD.
Survival and Follow-up After ACT
The median follow-up period after ACT for all 14 patients
was 22 weeks (range, 4-194 weeks). Nine patients died 4
to 36 weeks (median, 14 weeks) after ACT. Five patients
(36%) died of treatment-related causes; acute GVHD and
infectious complications (related to immunosuppression to
treat GVHD) contributed to death in 4 patients and
1 patient died of direct infectious complications. Three of
these patients died in complete remission, 1 with PR, and
1 patient died before a response could be determined. Four
patients died from disease progression (Hodgkin’s disease,
n = 3; myeloma, n = 1).
Four patients (recipients of 5 courses of ACT) remained
alive 27 to 194 weeks (median, 66 weeks) after ACT. One
patient remained in complete remission 33 weeks after his
second course of ACT (194 weeks after his first ACT),
1 patient had a continued PR 53 weeks after ACT, and
2 patients were alive with active disease 27 and 79 weeks
after ACT.
One patient with CR was alive 194 weeks after experi-
encing a complete remission from DLI without nonmye-
loablative therapy. This patient suffered a relapse 33 months
after initial ACT and was retreated with ACT consisting of
fludarabine and cyclophosphamide conditioning and allo-
geneic PBSC transplantation. By 17 weeks after his second
course of ACT this patient had a complete resolution of all
measurable disease except for a persistent osteolytic bone
lesion of unclear signiﬁcance.
Of the 5 surviving patients, 3 had greater than 99%
donor chimerism and 1 had 23% donor chimerism on day
60, and 1 had no detectable donor cells with follow-up of
more than 17 weeks after ACT.
DISCUSSION
Few effective treatment options exist for patients who
relapse after autologous SCT, and disease-free survival rates
are low [20]. The role of second autologous SCT is limited,
except perhaps in a small subset of patients with myeloma
[21]. Traditional allogeneic transplantation may cure a
minority of these patients but at the expense of excessive
morbidity and mortality. Disease-free survival rates of 0% to
30% have been reported for patients who undergo allograft-
ing for relapse after autologous SCT, and 25% to 85% of
patients may die from nonrelapse mortality [1,3,20,22,23].
ACT remains an attractive approach for these patients.
Overwhelming evidence shows that allogeneic grafts may
be associated with a potent GVT effect in patients with
hematologic malignancies. Initial indirect evidence for
GVT after allogeneic BMT [4] was confirmed by the
direct demonstration of GVT induction using DLI to
induce complete remission in many patients who had
relapsed after allogeneic BMT [5-9]. These data suggest
that it might be possible to harness the GVT potential of
donor leukocytes to treat a variety of hematologic malig-
nancies without the need for full ablative conditioning ther-
apy. We have shown previously that HLA-matched donor
leukocytes can be given safely to patients with a variety of
tumors and can produce sustained mixed chimerism and
GVT activity without the use of conditioning therapy, but
only in the most heavily pretreated patients [10]. Others
have shown that pretreatment with nonmyeloablative
immunosuppressive therapy may enhance engraftment of
allogeneic donor leukocytes and stem cells to permit
induction of GVT activity [11-15]. This approach is of
particular interest for heavily pretreated patients who
might benefit from ACT but who would have unacceptable
toxicity from traditional allogeneic marrow grafting. Sev-
eral reports describe treatment with ACT after relapse
from autologous SCT in small numbers of patients
[10,14,18,24,25], but little is known regarding toxicity and
response rates in this group of patients.
Engraftment kinetics after nonmyeloablative conditioning and allogeneic cell therapy. Kinetics of engraftment and maximal donor chimerism are
illustrated for the 7 patient recipients (8-14) of G-CSF–mobilized peripheral blood stem cell grafts. Samples tested on day 0 were tested within 1
hour after allogeneic cell infusion.
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Our results show that signiﬁcant responses to ACT can
be generated in a group of heavily pretreated patients. CR
was achieved in 6 patients, and 4 additional patients
achieved PR. Unfortunately, at the time of this report only
4 patients remained alive, including 1 in CR and 1 with an
ongoing PR. In addition, follow-up has been relatively
short, and the durability of these responses is unknown.
Several patients in CR either died of treatment-related
complications or ultimately relapsed. Five patients died of
complications related to GVHD and infection, and 4 died of
disease progression. Although the overall prognosis is par-
ticularly poor after relapse from autologous HSCT, it is not
known if survival was extended by ACT in any of these
patients. Only a randomized trial comparing ACT with con-
ventional salvage therapy would determine the long-term
beneﬁt of this strategy.
Our report has several unique features. This subset of
patients was heavily pretreated and had received prior high-
dose therapy with autologous stem cell support. Several
patients received DLI as primary therapy, a strategy based on
previous work using DLI to treat relapse after allogeneic
BMT. Given our previous data, we anticipated a high rate of
mixed chimerism, which was conﬁrmed in this analysis. Fur-
thermore, we have confirmed that unmobilized donor
mononuclear cells are sufﬁcient to generate signiﬁcant GVT
activity in some patients and can induce sustained mixed
chimerism. This is signiﬁcant because a GVT reaction, rather
than hematopoietic engraftment, remains the goal of this
method of allogeneic immunotherapy. Nevertheless, aplasia
was an anticipated and notable complication with this
approach. Although marrow aplasia in 2 recipients of unstim-
ulated DLI was successfully reversed with donor bone mar-
row, the use of G-CSF–mobilized PBSCs for immunotherapy
in subsequent patients protected against aplasia.
The requirements for GVT activity have not been
deﬁnitively elucidated, but donor T cells are clearly a major
component of GVT induction. The number of donor
T cells will be very similar in a G-CSF–stimulated periph-
eral blood leukapheresis product and an unstimulated donor
mononuclear cell product. It is unknown if unstimulated
DLI and GCSF–mobilized PBSC products contain donor
T cells with the same speciﬁcity and activity, although in our
limited number of patients both graft sources provided
significant GVT activity. It is notable that a recent study
compared DLI with G-CSF–stimulated donor PBSC prod-
ucts to treat relapsed chronic myeloid leukemia after allo-
geneic BMT and suggested that response rates were similar
regardless of the cell source used for ACT [26]. However,
transfer of a full PBSC product is more likely to result in
complete chimerism and engraftment of other immune
accessory cells (such as dendritic cells) required for full
expression of antitumor immunity. Therefore, PBSCs may
also have the advantage of being an appropriate platform for
subsequent DLI to augment GVT effects at later time
points. Our data are in keeping with several other trials of
nonmyeloablative allogeneic SCT showing that in some
patients maximal chimerism, GVT activity, and signiﬁcant
GVHD developed without additional DLI. The majority of
patients described in our report were not eligible for addi-
tional DLI because of active and signiﬁcant GVHD.
Our data also conﬁrm that a direct GVT effect can be
generated against Hodgkin’s lymphoma, even when this dis-
ease has been heavily pretreated with autologous SCT. The
importance of a graft-versus–Hodgkin’s disease effect has
been controversial. Lower relapse rates after allogeneic
SCT compared with autologous SCT for Hodgkin’s disease
have suggested that GVT effects are active in Hodgkin’s dis-
ease [27,28]. Several reports have demonstrated that either
DLI as primary therapy [10] or nonmyeloablative therapy
and allogeneic SCT [14,18,24,25] can result in a direct
graft-versus–Hodgkin’s disease effect. In our current series,
11 cases of Hodgkin’s disease treated with ACT resulted in
4 CRs and 2 PRs, providing definitive evidence of GVT
activity in this disease and demonstrating the potent antitu-
mor potential of ACT even in heavily pretreated patients. It
should be noted that the responses occurred after treatment
with either interferon or ﬂudarabine and cyclophosphamide.
Although we did not anticipate that these treatments would
have signiﬁcant activity in the patients who received them,
this possibility cannot be ruled out. With any nonmyeloab-
lative regimen, it is difﬁcult to separate conditioning regi-
men effects from the immunologic GVT response.
The treatment approach using nonmyeloablative therapy
and allogeneic SCT has resulted in a high rate of donor
chimerism; with variably intense but nonablative conditioning
therapy, at least partial chimerism rates of 73% to 100% have
been reported for a diverse group of patients [11-13,15,16].
Our prior data suggested that sustained mixed chimerism was
related to the degree of prior therapy [10]. In our current
series, all but 1 patient had at least partial sustained
chimerism with either no conditioning therapy or relatively
low doses of fludarabine and cyclophosphamide. This
chimerism rate contrasts with that in a similar group of
8 patients who had not received prior autografts but were
treated at our institution with an identical conditioning
therapy; only 2 of these 8 patients had sustained donor
chimerism. With ﬂudarabine and cyclophosphamide condi-
tioning, prior autologous transplantion predicted for donor
chimerism (P = .01, data not shown). It is also possible that no
conditioning therapy was required for any of these patients. If
the purpose of ACT is to harness the GVT effect of the
donor graft without dependence on the conditioning therapy
for an antitumor effect, then minimizing conditioning inten-
sity for heavily pretreated patients would seem appropriate. In
fact, ACT may be best designed to administer patient-speciﬁc
immunosuppression, and, for some patients, only minimum-
intensity conditioning may be necessary.
Table 4. Numbers of Patients With Graft-Versus-Host Disease (GVHD)
After Allogeneic Cell Therapy*
Grade of GVHD
0 I II III IV
Graft source
All sources (n = 14) 3 2 2 6 1
DLI (n = 7) 1 1 2 2 1
PBSCs (n = 7) 2 1 0 4 0
GVHD prophylaxis
No prophylaxis (n = 4) 0 1 2 0 1
CSA prophylaxis (n = 10) 3 1 0 6 0
*DLI indicates donor leukocyte infusions; PBSC, peripheral blood
stem cell; CSA cyclosporine.
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Toxicity after ACT is signiﬁcant; in our current series,
treatment-related toxicity accounted for 5 deaths, largely
related to GVHD and infections. It is important to note,
however, that the patients reported here represent a subset
of high-risk patients treated during 2 sequential trials of
ACT involving 36 patients. Treatment-related mortality in
this combined group of patients was 14% (5/36) (data not
shown). In other trials of nonmyeloablative ACT, treat-
ment-related mortality rates ranged from 6% to 33% [11-
14,18,29]. It is likely that the toxicity is enhanced in the
heavily pretreated patients that are the subject of our report.
Although the incidence of nonrelapse mortality reported
here may compare favorably with anticipated rates of 50%
to 85% for similar patients treated with traditional allo-
geneic BMT, toxicity remains a major concern.
Six of our 14 patients experienced grades III to IV acute
GVHD, which contributed to the death of 4 of these
patients. This result can be compared with other trials of
ACT reporting a 20% to 60% incidence of grades II to IV
acute GVHD [11-13,16,18,29] or a 5% to 15% incidence
of grades III to IV acute GVHD [14,17,30]. GVHD pro-
phylaxis with CSA alone, therefore, would appear to be
insufﬁcient in this group of patients. However, in a similar
group of patients with Hodgkin’s disease in relapse after
autologous SCT, grade III acute GVHD developed in 2 of
6 patients who received CSA with methotrexate [18]. Using
a more intensive conditioning regimen before allogeneic
SCT for patients with a variety of hematologic malignan-
cies, Slavin et al. reported that acute GVHD contributed to
the death of 4 (15%) of 26 patients when CSA alone was
administered for GVHD prophylaxis [13]. With a combina-
tion of CSA and mycophenolate mofetil (MMF), the Seattle
group reported that 36% of patients required additional
treatment for acute GVHD [24], and other data suggest
that MMF may further promote sustained chimerism [31].
Other regimens that have been used in this setting to mini-
mize GVHD include CSA with corticosteroids [11] and
tacrolimus with or without low-dose methotrexate [12]. It is
unknown if more intensive GVHD prophylaxis will inhibit
the potential for GVT activity. However, it is clear that
after allogeneic BMT or with the use of DLI to treat
relapse after allogeneic BMT, the severity of GVHD does
not correlate with GVT activity. In some circumstances it is
possible to generate a GVT reaction without clinically
apparent GVHD [32]. In fact, in our current series, the
patient with the longest CR, patient 4, had minimal skin
GVHD requiring no therapy.
Our high rate of GVHD is unlikely to be related to the
dose of T cells. The number of CD3+ cells administered as
DLI is similar or even lower than the dose included in a G-
CSF–stimulated stem cell product. Furthermore, the dose of
T cells administered to our patients is similar to that
reported in other trials of nonmyeloablative ACT [13,16,
29,30]. In studies that have not reported the CD3 content of
the graft, one can anticipate that CD3+ cells in a G-CSF–
mobilized leukapheresis product are typically 100 times
more abundant than CD34+ cells. Hence, most trials have
used a similar dose of T cells with variable rates of GVHD
[2,17,18,33,34]. Therefore, we hypothesize that heavily pre-
treated patients are at particularly high risk for signiﬁcant
GVHD. This high risk might be related to upregulation of
inflammatory mediators or enhancement of minor histo-
compatibility antigen presentation by injured tissues. Addi-
tional strategies to minimize GVHD are needed and will
likely include alternative prophylactic regimens, slower
tapering of immunosuppression, graft modification with
selective T-cell depletion or infusion [35,36], and perhaps
the use of donor cells genetically modiﬁed with suicide vec-
tors to directly inhibit alloreactive T cells [37].
At the time of relapse from autologous HSCT, many
patients already have extensive refractory disease, and ACT
has often been applied after many other treatment regi-
mens. It is possible that a strategy of autologous HSCT fol-
lowed by allogeneic immunotherapy may be a useful
sequential technique in some diseases that are susceptible to
both high-dose therapy and immunologic control. This
approach would allow administration of ACT to patients in
a minimal disease state. Carella et al. have shown that this
approach is both feasible and associated with acceptable
toxicity [38]. They reported a relatively low incidence of
GVHD that may have been related to the use of both CSA
and methotrexate but also perhaps to the fact that some of
these patients had minimal residual disease or were earlier
in their disease course.
Consistent engraftment combined with demonstration of
GVT activity suggests that ACT may be an acceptable treat-
ment approach for patients who relapse after autologous
HSCT. However, toxicity is significant and survival rates
remain low in this group of very heavily pretreated patients,
and alternative strategies to improve the safety of ACT are
being investigated. The occurrence of typical and unusual
toxicities including severe GVHD, frequent cytomegalovirus
reactivation, aspergillus, mucomycosis, neurologic toxicity,
and probable progressive multifocal leukoencephalopathy
highlights the importance of treating this group of patients
with caution on carefully designed clinical trials.
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